search

Barnabie Agatep, MPH

Director, Health Economics and Outcomes Research

A woman with dark hair pulled back, wearing a light-colored blazer, smiles while sitting indoors with green plants in the background at Barnabie Agatep's studio.

Barnabie leads real-world evidence studies for life science customers across chronic conditions, rare disease, and oncology. Barnabie utilizes her expertise in retrospective study design to implement research studies using commercial, Medicaid, and Medicare closed claims to understand the patient journey, treatment patterns, unmet needs and demonstrate product value. Her work has been published across a wide range of therapeutic areas, including serious mental illness, cardiology, and oncology.

Prior research-focused roles include Avalere Health, where she managed evidence generation studies; Medco Research Institute conducting retrospective research analysis to illustrate the value of pharmacogenomics and personalized medicine; and Pfizer Inc., where she conducted real-world evidence studies, developed dossiers, and other outcomes research initiatives in support of product launch. Barnabie has a Master of Public Health in epidemiology from the University of Medicine and Dentistry of New Jersey School of Public Health and a Bachelor of Science in Public Health from The Richard Stockton College of New Jersey.

Connect on LinkedIn
Authored Content
Placeholder
Cardiovascular

Real-World Adherence and Persistence Among U.S. Medicare Beneficiaries Initiating Advanced Lipid Lowering Therapies

Accepted for presentation at American Society for Preventive Cardiology 2026 Congress on CVD Prevention. Findings available upon request. Contact us for more information.

Placeholder
Cardiovascular

Lipoprotein(a) Impact on Atherosclerotic Cardiovascular Disease and Major Adverse Limb Events Among Patients With Peripheral Artery Disease

Accepted for presentation at American College of Cardiology. Findings available upon request. Contact us for more information.

Placeholder
Cardiovascular

Impact of Elevated Lipoprotein(a) on Cardiovascular Events in Patients With Premature ASCVD: A Nationally Representative Sample of U.S. Medicare, Medicaid, and Commercial Enrollees

Accepted for presentation at American Heart Association. Findings available upon request. Contact us for more information.

A man lying on a couch with his eyes closed, wearing an oxygen mask and holding a nebulizer, appearing unwell—an image often used in Data Sets for Healthcare to illustrate respiratory conditions.
Life Sciences

Breathing Easier: Why Timing Matters in COPD Treatment

Discover how prompt COPD treatment significantly reduces flare-ups and severe heart risks, and improves patient outcomes.

Read More →
Placeholder
Hematology, oncology

Study on Real-World Outcomes with Ibrutinib Dose Reduction

This study examined treatment patterns and outcomes among people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who began ibrutinib and later experienced a treatment-related adverse events.

Read More →
Placeholder
Respiratory

Promptly Escalating to Budesonide/Glycopyrronium/Formoterol From Dual Therapy Reduces Exacerbations and Cardiopulmonary Events in Patients with COPD (MITOS EROS+CP Study)

Promptly escalating from dual therapy to BGF triple therapy after a COPD exacerbation linked to fewer exacerbations, events. ERS 2024 MITOS EROS+CP study.

Read More →
Share